U.S. Rx Drug Spend Will Top $500 Bil. Annually In 10 Years, CMS Projects
This article was originally published in The Pink Sheet Daily
Centers for Medicare & Medicaid Services predicts that the U.S. annual drug spend will reach $520 bil. in 2013, close to triple the expenditure in 2003. The CMS projections confirm that the rate of growth is slowing as top-selling drugs lose patent protection and costs are shifted to patients.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.